A phase II clinical trial has begun in the US for a liquid form of botulinum toxin. Galderma, the healthcare company behind the trial say that, if it is successful, it will be beneficial for both patients and practitioners.
The multicentre, dose-range study will assess the safety and effectiveness of Galderma’s internally developed liquid botulinum toxin, which is used to treat glabellar lines.
Currently, all botulinum toxin comes in powder form, and has to be prepared by combining with saline before use. Galderma say that a liquid form would not only improve patient experience, but be beneficial for aesthetic outcomes.
Humberto C. Antunes, President and CEO of Galderma, said of the trial: “This trial initiation demonstrates Galderma’s commitment to innovation in the aesthetic market and is designed to strengthen and complement our current neurotoxin franchise.”